We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Flow-Through Testing Technology Expanded for HIV Diagnosis

By HospiMedica staff writers
Posted on 24 Dec 2007
Print article
A new range of rapid HIV testing products is being produced utilizing a new scientific test platform.

The core technology platform, which is the basis a new generation of infectious disease testing products, includes a rapid flow-through diagnostic device, assay, and multi-functional buffer.

The rapid diagnostic tests were developed by MedMira (Halifax, Canada) and are to be sold by the German company Vitest (Hennigsdorf, Germany). This is the first shipment of MedMira's private label product to a distributor in Europe. Under the private label agreement, Vitest will market and sell the new product under the Vitest brand and it will be a part of the Vitest suite of rapid testing products.

"Our rapid flow-through technology platform has an endless list of potential applications, for which our current product pipeline has barely scratched the surface,” said Hermes Chan, president and CEO of MedMira. "Our strategic goals involve the pursuit of a wide range of opportunities to diversify not only our own product portfolio, but also to make available a private label or OEM [original equipment manufacturer] capability to fill the needs of our partners. We are pleased to welcome Vitest as our first partner in this endeavor.”

MedMira is a developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics, and individuals worldwide with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal, MiraWell, MiraCare, and Multiplo brands. MedMira's rapid HIV test has achieved regulatory approvals in Canada, the United States, China, and the European Union.

The Maple Biosciences division of MedMira develops and commercializes diagnostic instruments based on two new biosensor-based technology platforms. Solutions developed by The Maple Biosciences division of MedMira enable routine laboratory tests to be performed in minutes, increasing laboratory automation, and streamlining the diagnosis of multiple conditions and diseases.


Related Links:
MedMira
Vitest
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Automated Blood Typing System
IH-500 NEXT
New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
New
Vibrio Cholerae O1/O139 Rapid Test
StrongStep Vibrio Cholerae O1/O139 Antigen Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.